Merck still faces pressure ahead of the earnings season, with competition in the GLP-1 space weighing on valuations; WuXi Biologics continues to be concerned about the risk of foreign capital withdrawal; Moderna still has support from seasonal demand; two Hong Kong-listed biotech companies, GenScript and YAOJIE ANKANG, each have their own catalysts.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
